Research reading
Blood, human or animal, antisera, other blood fractions and immunological products: immunological products, unmixed, not put up in measured doses or in forms or packings for retail sale demand and the Sweden (SWE) to FIN (FIN) lane
FIN (FIN) reported $5.5M of blood, human or animal, antisera, other blood fractions and immunological products: immunological products, unmixed, not put up in measured doses or in forms or packings for retail sale imports in 2024. Sweden (SWE) accounted for 0.1% of the observed market and reported $4.1K in exports on this lane.
The latest annual values eased slightly, while the longer available history shows +28.6% buyer growth and -24.4% exporter growth. The page separates reported values from projections and indicators.
